Key words: dexamethasone, mouse, placental development, prenatal stress ABSTRACT: Prenatal treatment of dexamethasone, a synthetic stress hormone, leads to low birth weight and affects adult pathophysiology. Because fetal growth and survival are critically dependent on successful placental development, we aimed to investigate the effects of prenatal dexamethasone exposure on placental growth and function, particularly focusing on issues surrounding the time of stress exposure in a developmental context. Dexamethasone was administered at a dosage of 1 mg/kg BW (DEX1) or 10 mg/kg BW (DEX10) intraperitoneally at gestational d 7.5, 8.5, and 9.5 in pregnant mice. Placentas were then dissected at gestational d 11.5 and 18.5. Placental size and weight were reduced at d 11.5 in a dose-dependent manner (P = 0.11 for saline vs. DEX1 and P < 0.001 for DEX1 vs. DEX10 in size; P = 0.34 for saline vs. DEX1 and P < 0.01 for DEX1 vs. DEX10 in weight). In contrast, a considerable heterogeneity was shown at d 18.5, especially in DEX10-treated mice. Some placentas were small and malformed whereas some were enlarged with structural abnormalities in spongiotrophoblasts and labyrinth layers. Although placental overgrowth under such condition seemed to compromise fetal demand for nutrient supply, disorganized cell structure with reduced fetal vasculature observed in large placentas suggests that prenatal stress exposure during the early gestational period negatively affects placental development and effi ciency.
INTRODUCTION
Approximately 20% of pregnancies result in miscarriage in humans, and it is believed that most spontaneous abortions take place during the fi rst 3 wk of pregnancy, which is the time required for placentation (Malassine and Cronier, 2002) . Maternal stress has long been suspected as a possible cause of miscarriage; however, the relationship between the strength of stress and the specifi c responses within the placenta remains unclear.
The placenta is an extra-embryonic tissue that lies between maternal and fetal compartments and plays a pivotal role in the materno-fetal exchange of substances. Because of the essential role of the placenta in the survival of the fetus (Rossant and Cross, 2001) , understanding the full nature and extent of placental responses against adverse environment such as stress is important in building up our knowledge of cause and effect of spontaneous abortion and other pregnancy complications. Indeed, evidence from animal models with mouse, rat, and guinea pig indicate that glucocorticoids infl uence placental effi ciency through changes in placental morphology, hormone synthesis, and transport physiology (Fowden et al., 2009) . However, it is not easy to generalize individual fi ndings because each experimental condition gives distinct effects depending on the type and timing of the challenges being analyzed.
In this study, we examined the effect of prenatal glucocorticoids on placental maturation in mice after the administration of dexamethasone at a specifi c time (d 7.5 to 9.5 of gestation), which is important for placental formation and, moreover, roughly corresponds to the third week of human pregnancy. We hypothesized that maternal stress or injection of synthetic glucocorticoids at this developmental stage would unfavorably affect placental development and eventually would adversely affect embryonic development.
MATERIALS AND METHODS
Experimental procedures were approved by the Animal Care and Use Committee of Yonsei University College of Medicine.
Animal and Tissue Preparations
About 10-to 12-wk-old CD1 mice from a commercial outbred stock of the Institute for Cancer Research (ICR) were mated. Vaginal plugs were detected the next day, which was considered as 0.5 d postcoitum (dpc). For 3 consecutive days (d 7.5, 8.5 , and 9.5 of gestation), 16 pregnant females were injected with dexamethasone 21-phosphate salt (Sigma-Aldrich, St. Louis, MO) intraperitoneally, with a dosage of 1 mg/kg BW (DEX1) or 10 mg/kg BW (DEX10) using 8 mice per group. Six pregnant females received equivalent amounts of saline to serve as controls. One-half of each group was sacrifi ced by cervical dislocation at 11.5 dpc and the remaining mice were sacrifi ced at 18.5 dpc. The embryos and placentas were harvested in PBS separately and their size and weights were measured. Placental size was determined by measuring the largest diameter. One-half of the samples from the same litter were fi xed in 4% paraformaldehyde for histological purposes. The other samples were frozen and later used for RNA extraction.
Histological and Morphometric Analyses
For histological analysis, paraformaldehyde-fi xed placental tissues were dehydrated through graded alcohols, cleared in benzene, and embedded in paraffi n using standard procedures. Paraffi n-embedded tissues were then sectioned at a thickness of 5 μm. The paraffi n sections were deparaffi nized, hydrated through graded xylene alcohol, and stained with hematoxylin and eosin. After photographing, computer-assisted morphometric analyses were performed using Image J software (available at http://rsb.info.nih.gov) to measure the surface area of the labyrinth and spongiotrophoblast regions. The sections taken from the part of the placenta that were the closest to the center were used for the image analysis. Four to seven sections (from different litters) per group were analyzed.
In Situ Hybridization
For in situ hybridization, paraformaldehyde-fi xed placentas were dehydrated in a 30% sucrose solution and embedded in Optimal Cutting Temperature (OCT) compound (Tissue-Tek; Sakura Finetek, Torrance, CA). The tissues were then sectioned at a thickness of 12 μm, placed onto superfrost slides (VWR Scientifi c, West Chester, PA), and stored at -70°C. To generate riboprobes for Trophoblast-specifi c protein α (Tpbpα), the PCR products from a set of primers (sense: 5′-GCA  CCT GTG CAG GAG AAC TC-3′; antisense: 5′-CAT  CAG GCC ATC TCT TGG AG-3′) were cloned into pBluescript SK II+ vector (Stratagene, La Jolla, CA). Digoxygenin-Uridine-5´-triphosphate(UTP)-labeled sense and antisense riboprobes were generated by in vitro transcription. In situ hybridization was conducted using standard procedures (Morsil et al., 1998) . The slides were incubated with Nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate for color reaction.
Immunohistochemistry
Paraffi n-embedded sections were used for immunohistochemistry. After deparaffi nization and rehydration, the slides were boiled in an antigen unmasking solution (Vector Laboratories Inc., Burlingame, CA) for 2 min and cooled for 30 min at room temperature. Then the sections were incubated in a blocking solution (5% fetal bovine serum and 2% BSA) for 1 h at room temperature. Excess serum was wiped off and then the sections were incubated with primary antibody (1:100 dilution of Laminin antibody, catalog number ab11575; Abcam, Cambridge, MA) overnight at 4°C in a humidifi ed chamber. The sections were washed and incubated with goat anti-rabbit secondary antibody conjugated with Alexa Fluor 488 (Invitrogen, Carlsbad, CA; 1:200 dilution) for 1 h at 4°C. Then the sections were washed 3 times with PBS and counter-stained with 4'-6-diamidino-2-phenylindole. Fluorescent images were taken with an Olympus IX70 fl uorescence microscope (Olympus Optical, Hamburg, Germany) with a 488 excitation wavelength.
RNA Isolation and Reverse Transcription PCR
Total RNA was isolated from whole placentas using Trizol reagent (Invitrogen). Reverse transcription was performed with 1 μg of RNA using ImProm-ll Reverse Transcriptase (Promega, Madison, WI). Then PCR was performed in triplicate using G Taq polymerase (Cosmogenetech, Seoul, Korea). The PCR amplifi cation was performed under the following conditions: initial denaturation for 5 min at 94°C and then 28 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 1 min. The primer sequences were as follows: for placenal lactogen II (PLII), 5′-GCG CAG GGA TAC ACA TAA AG-3′ (sense) and 5′-GTC TTG TGT CCA CTT CCC CT-3′ (antisense); for proliferin-related protein (Prp), 5′-ATG TTT TCC TTC TGC CTG CG-3′ (sense) and 5′-GCA GGA ATG GAT GAA CAC AG-3′ (antisense); for vascular endothelial growth factor (Vegf), 5′-CTT GTT CAG AGC GGA GAA AG-3′ (sense) and 5′-GTC AAC GGT GAC GAT GAT GG-3′ (antisense); and for β-actin, 5′-CAT GTT TGA GAC CTT CAA CAC CCC-3′ (sense) and 5′-GCC ATC TCC TGC TCG AAG TCT AG-3′ (antisense). The sequences of PCR primers for Tpbpα and Distal-less 3 (Dlx3) were shown previously (Selesniemi et al., 2005) .
For quantifi cation, Multi Gauge V3.0 software (Fuji, Tokyo, Japan) was used.
Real-Time PCR and Data Analysis
Real-time PCR of Vegf was performed using the Effect of prenatal dexamethasone treatment on size and weight of mouse placenta. The placental size (A) and weight (B) were measured at embryonic d 11.5 (E11.5) and embryonic d 18.5 (E18.5) from saline-, dexamethasone administered at a dosage of 1 mg/kg BW (DEX1)-, and dexamethasone administered at a dosage of 10 mg/kg BW (DEX10)-treated placentas. The values are expressed as mean ± SD. Statistical signifi cance was determined by ANOVA, P < 0.05. Post hoc test: *P < 0.0167 vs. saline-treated group. **P < 0.0167 vs. DEX1-treated group. Size and weight distributions at E11.5 (C and D) and E18.5 (E and F) were presented as percentages of the total population. The sample sizes used in the measurements of placental size and weight are presented in the graph. Placentas in each group are from 3 to 4 littermates.
Applied Biosystems 7300 Real-Time PCR System with Power SYBR Green PCR Master Mix (Applied Biosystems, Foster, CA). The PCR cycling program consisted of 2 min at 50°C and 10 min at 95°C followed by 40 cycles of 15 s at 95°C, 30 s at 58°C, and 40 s at 72°C. The expression of β-actin was used as an internal control because its expression was not infl uenced by experimental conditions. The relative gene expression was quantitatively analyzed based on the 2 [-ΔΔC(T)] method (Livak and Schmittgen, 2001 ).
Statistical Analysis
The values of placental and embryonic size and weight were expressed as means ± SD. All the other values were expressed as means ± SEM. One-way ANOVA (SAS Inst. Inc., Cary, NC) was used for mean comparisons. If the ANOVA was signifi cant (P < 0.05), post hoc analysis was conducted with a Bonferroni correction applied, resulting in a signifi cance level set at P < 0.0167. A Student's t-test was used for comparison of 2 independent group means (saline vs. DEX10-treated) for gene expres- sion data.
RESULTS

Effects of Dexamethasone on Placental Growth
To examine the effect of prenatal exposure of dexamethasone on placental development and growth, we administered dexamethasone 3 times at gestational d 7.5, 8.5, and 9.5. At d 11.5 of gestation, dexamethasonetreated placentas were smaller and weighed less compared with saline-treated placentas in a dose-dependent manner (P = 0.1053 for saline vs. DEX1 and P = 0.0008 for DEX1 vs. DEX10 in size; P = 0.3413 for saline vs. DEX1 and P = 0.0024 for DEX1 vs. DEX10 in weight; Figures 1A and 1B, left) . However, at gestational d 18.5, DEX1-treated placentas showed increased placental weight (P = 0.0039) whereas DEX10-treated placentas showed size and weight reduction compared with DEX1-treated groups (P < 0.001 in size and in weight). As a result, there were no differences in size or weight compared with those of saline-treated controls. Moreover, there was wide individual variation among the DEX10-treated placentas (Figures 1A and 1B, right) .
To defi ne the exact feature of size and weight distributions, a number of specimens in the appropriate subrange were plotted ( Figures 1C through 1F) . At d 11.5, the saline-treated control placentas had a restricted size range, with the majority of the group ranging from 6.1 to 8 mm ( Figure 1C ). The DEX1-treated placentas also had a peak in the same size range, but the proportion was slightly reduced from 80 to 68% ( Figure 1C ). Compared with this, more than 50% of DEX10-treated placentas were small, with a range of 4.1 to 6 mm ( Figure 1C ). The placental weight at d 11.5 showed a similar pattern to that of the size distribution graph ( Figure 1D ). The largest bar in the DEX1-and DEX10-treated groups shifted to the left, showing dexamethasone dose-dependent placental weight reduction. The size and weight distributions at d 18.5 defi ned the reason why the mean values in the DEX10-treated group were similar to those of the control group. The major population in the DEX1-treated placentas had increased size and weight at gestational d 18.5 whereas the DEX10-treated placentas showed a dispersed distribution in both size and weight ( Figures  1E and 1F ). The size of about 67% of the control placentas ranged from 6.1 to 8.0 mm. On the other hand, the major population was divided into 3 equal parts in the DEX10-treated group (≤6.0 mm, 34.5%; 6.1 to 8.0 mm, 31%; >8.0 mm, 34.5%; Figure 1E ). Similarly, a large number (57%) of the control placentas were included in the weight range of 61 to 100 mg whereas only 31% of the DEX10-treated placentas were in this range. Others were evenly dispersed across the range ( Figure 1F) . Interestingly, we found that the embryos from 7 (2 out of 27) and 21% (6 out of 29) of placentas weighing <40 mg in the DEX1-and DEX10-treated group, respectively, did not survive. Placental effi ciency, the ratio of fetal weight to placental weight, is often used to measure the relative capacity of a placenta to support fetal growth (Fowden et al., 2009 ). We determined placental effi ciency only with the placentas connected to the developing embryos. Placental effi ciency was slightly decreased in the DEX1-and DEX10-treated groups at d 11.5 of gestation, but there was no difference detected compared with the saline-treated controls (Table 1) . However, placental effi ciency was more dramatically decreased at d 18.5 because the placental weight was rather increased in both the DEX1-and DEX10-treated groups (P < 0.0001 and P = 0.0020, respectively) compared with the controls (Table 1). Particularly, if we count only the enlarged placentas weighing >100 mg and their embryos, the placental effi ciencies were more severely reduced by 40 and 44% in the DEX1-and DEX10-treated groups, respectively (this category was not presented in Table 1 ).
Effects of Dexamethasone on Placental Structure
Histological analysis was performed to examine structural changes in placentas after the early treatment of dexamethasone during pregnancy. Hematoxylin and eosin staining can distinguish the border of the maternal decidua and fetal-derived spongiotrophoblasts and labyrinth layers (Natale et al., 2006) . The dexamethasone-treated placental samples at d 11.5 of gestation showed structural abnormalities, with a marked reduction of fetal regions, compared with the saline-treated control placentas (Figures 2A through 2F) . The DEX1-treated placentas exhibited no obvious abnormalities in cell density in the region of vascular labyrinth ( Figures 2B and 2E ) whereas the DEX10-treated placentas were smaller and highly disorganized in both the spongiotrophoblast and labyrinth regions, accompanying large empty spaces (Figures 2C and 2F ). Because we observed almost even distribution over a large range in placental size by DEX10 treatment at gestational d 18.5, we focused on the large placentas for histological analysis and found that the spongiotrophoblast region was expanded but less compact in the dexamethasone-treated samples ( Figures 2G through  2L) ; furthermore, this phenotype was much more severe in the DEX10-treated samples ( Figures 2I and 2L) .
This phenomenon was also demonstrated by in situ hybridization using digoxigenin-labeled RNA probes for Tpbpα, a spongiotrophoblast-specifi c marker. In contrast to the well-organized Tpbpα-positive cell layer in the saline- treated control placentas, the cells in the dexamethasonetreated placentas showed disorganized distribution at both d 11.5 and 18.5 of gestation (Figure 3 ). The expression of Tpbpα in DEX1-treated placentas did not appear to refl ect a change in the structural integrity of the spongiotrophoblast cell layers ( Figures 3B and 3E) ; however, the changes were clearly visible in the DEX10-treated placentas at both stages ( Figures 3C and 3F ).
To quantitatively determine the effect of dexamethasone on the rate of change of the surface area in the fetal region including the spongiotrophoblast and labyrinth, a morphometric analysis with the hematoxylin and eosin-stained sections was carried out. At d 11.5, the surface area of the fetal region was reduced by dexamethasone in a dose-dependent manner (P = 0.0156 for saline vs. DEX1 and P = 0.0008 for saline vs. DEX10; Figure 4A ). Although the reduction of both the spongiotrophoblast and labyrinth regions contributed to making the placenta small, the shrinkage of the labyrinth region (P = 0.0064) had more impact ( Figure 4A ). On the contrary, at d 18.5, although both DEX1 and DEX10 treatments did not lead to increases in the surface area of the fetal region, there was still enlargement of the spongiotrophoblast region (P = 0.0082) in DEX10-treated placentas ( Figure 4B ). Gene expression for Trophoblast-specifi c protein α (Tpbpα), Distal-less 3 (Dlx3), placenal lactogen II (PLII), and proliferin-related protein (Prp) in saline-, dexamethasone administered at a dosage of 1 mg/kg BW (DEX1)-, and dexamethasone administered at a dosage of 10 mg/kg BW (DEX10)-treated placentas at embryonic d 18.5 were analyzed by reverse transcription PCR and the results were semiquantitatively analyzed. Each RNA sample numbered from S1 to D10c represents the tissue RNA pooled from 4 placentas of the same litter. β-actin was used to normalize the gene expression in each sample. For each gene, the relative quantity is based on the expression of each sample versus the expression of saline-treated sample 1 (S1). (C) The expression of vascular endothelial growth factor (Vegf) at embryonic d 11.5 (E11.5) and embryonic d 18.5 (E18.5) were analyzed by real-time PCR. The RNA samples at 18.5 d of gestation were the same as the ones used in (A). The pooled RNA was also prepared in the same way from E11.5 placental tissues and used for real-time PCR. Graphs are depicted as mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the corresponding control values in a t-test. were measured by morphometric analysis. The dexamethasone administered at a dosage of 1 mg/kg BW (DEX1)-and dexamethasone administered at a dosage of 10 mg/kg BW (DEX10)-treated placentas were stained with hematoxylin and eosin and images then were analyzed and quantifi ed using Image J software (available at http://rsb.info.nih.gov). Saline-treated placentas were used as controls. The values are expressed as mean ± SEM. Statistical signifi cance was determined by ANOVA, P < 0.05. Post hoc test: *P < 0.0167 vs. saline-treated group.
Effects of Dexamethasone on Placental Gene Expression
Because gross structural abnormalities were found in the dexamethasone-treated placentas, we examined whether these phenotypes were accompanied by alteration of gene expression. The reverse transcription PCR results with RNA samples from d-18.5 placentas showed no difference between the saline-treated control and DEX1-treated groups because of the individual variations in the dexamethasone-treated group. However, there was a tendency toward slight upregulation of Tpbpα in DEX10-treated cells compared with the saline-treated controls (P = 0.0032; Figures 5A and 5B). In contrast, PLII and Prp genes, 2 major classes of placental hormones synthesized during mid to late gestation, were downregulated by DEX10 treatment (P = 0.0002 for Prp; Figures 5A and 5B). A homeodomain transcription factor essential for the development of the labyrinth layer (Morasso et al., 1999) , Dlx3, also showed a reduction by DEX10 treatment (P = 0.0469). Because placental expression of Vegf is known to be associated with an increase in labyrinthine vascularity (Carmeliet et al., 1996; Ferrara, 2004) , the expression level of Vegf in the control and dexamethasone-treated samples were monitored at both d 11.5 and 18.5 via real-time PCR. The expression of Vegf was greatly downregulated (P = 0.0452) by DEX10 at d 18.5 ( Figure 5C ).
Fetal Blood Space in Dexamethasone-Treated Placentas
Proper development of the placental vascular system is essential to supply the metabolic substrates from a dam to her fetus. To examine whether dexamethasone led to changes in fetal capillaries in the labyrinth, the distribution of laminin protein was analyzed by immunofl uorescence staining. Laminin, a major component of epithelial basement membranes, can be used to identify fetal vessels that make up the placental labyrinth layer (Senior et al., 1988) . In the control placentas, laminin staining was strong on the basal membrane of the fetal vessels that were evenly distributed throughout the labyrinth (Figures 6A and 6D) . In contrast, the signals for laminin were very weak both in the DEX1-( Figures 6B and 6E ) and DEX10-treated placentas ( Figures 6C and 6F ).
DISCUSSION
In this study, we showed that administration of highdose dexamethasone during early pregnancy negatively affects the development of the placenta and can lead to early pregnancy loss. In a previous study to select a clinically relevant dose of corticosteroids, administration of 0.1 mg of dexamethasone to pregnant mice enhanced fetal lung maturity and did not severely impede fetal survival or growth (Christensen et al., 1996) . On the other hand, administration of 0.1 mg/kg BW of dexamethasone at mid gestation or a continuous release of 0.2 mg/(kg BW·d) over a period of days via a subcutaneously implanted osmotic pump previously were shown to induce intrauterine growth retardation (IUGR) in rats (Benediktsson et al., 1993; Levitt et al., 1996; ; therefore, this method has been used to investigate the molecular effect of dexamethasone on murine placenta (Ain et al., 2005; Ozmen et al., 2011) . However, in the current study, we administered a high dose of dexamethasone, large enough to cause fetal abnormalities or prenatal death, in pregnant mice to investigate the effect of maternal exposure to severe stress during an early stage of pregnancy on the fetus and placenta. Previously, administration of 10 mg/kg BW of triamcinolone hexacetonide, a kind of intermediate-acting synthetic glucodorticoid, intramuscularly to ICR mice at various stages of pregnancy was shown to induce mandibular growth retardation and palatal malformation (Silbermann and Levitan 1979) . More recently, C57BL/6J mice treated with 6 mg/kg BW of dexamethasone intraperitoneally at d 10 to 12 of gestation showed a signifi cantly greater incidence of cleft palate at d 17.5 of gestation (Zhou et al., 2011) . Based on these previous fi ndings, we chose to use 1 and 10 mg/kg BW of dexamethasone in this study.
In general, a decrease in placental effi ciency is observed under hypoxemia, restriction of oxygen availability by maternal anemia, or reduction in uterine blood fl ow. However, the effi ciency can be increased by restriction of dietary calories or protein deprivation (Fowden et al., 2009) . Studies with animal models have provided evidence of the effect of synthetic glucocorticoids on placental effi ciency. In most cases, a synthetic glucocorticoid was administered in mid to late pregnancy to mimic and identify side effects of glucocorticoids. It was shown that prenatal exposure to glucocorticoids increased placental effi ciency even though both fetal and placental weights were reduced Ain et al., 2005; Hewitt et al., 2006; Braun et al., 2007; Ozmen et al., 2011) .
Unlike many previous studies, our study focused on the effect of glucocorticoids on placental development after the administration of dexamethasone at early postimplantation stages. The mouse allantois begins to form at gestational d 7 and spans the exocoelom and fuses with the chorion by d 9 (Rossant and Cross, 2001) . Because it is a critical time for the development of the chorioallantoic placenta and defects in placentation are closely associated with abortion or pregnancy complications such as preeclampsia, it is worth studying how prenatal exposure to glucocorticoids during this time infl uences placental development.
In our mouse model system, prenatal dexamethasone exposure during early pregnancy showed an effect as early as gestational d 11.5 with reduction in fetal and placental size/ and weight. In contrast, dexamethasone led to a substantial decrease in placental effi ciency at gestational d 18.5. Although the mean value of embryonic weight was not signifi cantly reduced at d 18.5 of gestation, the weight distribution over a wide range in the DEX10-treated group implies that DEX10 had a more severe effect on the placenta. About 30% of placentas were extremely small and were not able to fully overcome adverse conditions. As a result, we found collectively that 35.8% of the embryos were found dead or resorbed at d 18.5 of gestation by DEX10 treatment, probably due to the placental insuffi ciency, which implies that extremely low-weight placentas had insufficient functionality to support embryonic development (Kim et al., 2011) . Meanwhile, another 30% of the placentas became overgrown probably by a compensatory effect on placental growth. Importantly, there were several human cohort studies showing correlations between adverse environmental factors during pregnancy, such as restricted maternal nutrition and maternal psychosocial stress, and compensatory placental growth (Lumey, 1998; Tegethoff et al., 2010) . Similar results also were reported in studies using sheep as an animal model (Faichney and White, 1987; McCrabb et al., 1991 McCrabb et al., , 1992 . Because increased placental weight was shown to be a risk factor for hypertension in the offspring and maternal cancer in human (Naeye, 1987; Barker et al., 1990) , prenatal stress, together with other maternal risk factors, can be clinically signifi cant. Although there was not enough information on the stress-exposure time in a recent human cohort study (Tegethoff et al., 2010) , other human and animal studies suggest that moderate under nutrition in early to mid pregnancy leads to an increased placental weight to compensate for a reduction in maternal caloric intake (Faichney and White, 1987; McCrabb et al., 1991 McCrabb et al., , 1992 Lumey, 1998 ), which appears to be suffi cient to maintain fetal growth under adverse conditions (McCrabb et al., 1991 (McCrabb et al., , 1992 Lumey, 1998) . Our results showing a 15% reduction in fetal weight at d 11.5 but no signifi cant weight loss at d 18.5 with a low dose of dexamethasone (DEX1) are in agreement with these previous fi ndings. Taking all of these important points into consideration, the relationship between the timing of stress exposure and developmental events occurring at that particular time may be important to understand the cause and effect of prenatal stress on fetal development. A recent human cohort study regarding the effects of maternal cortisol and psychological stress on infant development strongly supports the idea that the effects are dependent on the time of exposure (Davis and Sandman, 2010) .
Previous microarray data revealed that a large number of placental genes were differentially regulated in IUGR human pregnancies (Sitras et al., 2009 ) and in dexameth-asone-treated mice (Baisden et al., 2007) . Other studies using rodent models also have reported the changes in mRNA or protein expression levels of specifi c genes, such as placental vasculogenic or apoptosis-related genes, placental hormone genes, and nutrient transporters; however, the changes in gene expression patterns and the cellular responses were specifi c depending on the timing and the duration of the treatment (Hahn et al., 1999; Waddell et al., 2000; Ain et al., 2005; Hewitt et al., 2006; O'Connell et al., 2011; Ozmen et al., 2011) . The developmental stage and the strength of stress stimuli are, therefore, the main determinants of gene circuits and precise tuning of the cellular response to prenatal stress. In our system, dexamethasone-induced expansion of surface area and increased placental weight in late pregnancy can be regarded as a mechanism of adaptation to cope with unfavorable conditions. We do not rule out the possibility that a high dose of dexamethasone may cause placental edema and may contribute to swelling in the spongiotrophoblast region and placental weight increment; however, the disruption of cellular organization in the spongiotrophoblast and labyrinth layers along with concomitant changes in gene expression in large placentas refl ect certain functional defects in placental physiology. Beyond its role as a structural support between the outermost giant cells and the innermost labyrinth layer, spongiotrophoblast cells produce several layer-specifi c secreted factors, including soluble Fms-like tyrosine kinase 1 (Flt1) and Prp (Cross et al., 2002) . Despite no large change in Tpbpα expression, disorganization of Tpbpα-positive cells and downregulation of Prp in the DEX10-treated placentas by d 18.5 of gestation clearly showed structural and physiological damage in the middle layer. More interestingly, our data showing loss of Dlx3 expression from the DEX10-treated placentas in which the embryo failed to develop (D10c in Figure 5A ) indicates a good correlation with its severe phenotype. A previous report showing placental defects and embryonic lethality in mice lacking Dlx3 (Morasso et al., 1999) as well as our observations of an altered pattern of gene expression in this study led us to determine the effect of dexamethasone in the formation of fetal blood vessels. Consistent with a previous result showing dexamethasone-induced inhibition of placental Vegf expression in rats (Hewitt et al., 2006) , our results showing reduced expression of Vegf and laminin suggest that glucocorticoid exposure in early pregnancy induces improper placental development and can lead to intrauterine growth retardation or fetal death, depending on the severity of functional defects. Because placentas were pooled without regard to sex in the present study, further work is needed to determine whether sex of the fetus and the placenta infl uence the response to dexamethasone.
In summary, this study provides an insight into the effects of maternal dexamethasone treatment at a specifi c time point on early embryonic and placental development. Compared with the previous reports, the dose and duration of dexamethasone treatment we applied to our mouse model gave a unique feature: some placentas showed complementary growth to adapt to an adverse condition, but some maladapted ones failed to support fetal growth. In the context of timing and stress response, the present data reemphasize the notion that prenatal stress exposure, particularly early in pregnancy, can lead to a long-term effect in placental function and physiology and is eventually associated with an increased risk of abortion. Although it is not clear at the moment whether the altered gene expression was a direct or an indirect effect of dexamethasone, the combination of both genetic and epigenetic changes are presumed to be derived from prenatal glucocorticoid exposure and can dictate specifi c responses, depending on the developmental context.
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